Compounds as cannabinoid receptor ligands and uses thereof
View Patent ↗The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , R 4 , and L 1 are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1a , R 2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
1. A compound according to formula (I),
or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof,
wherein
R 1 is A-alkylene-;
R 2 is hydrogen;
R 3 is hydrogen or alkyl
R 4 is phenyl, wherein the phenyl is unsubstituted or substituted with 1-5 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkyl, alkoxyalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkyl-S—, alkyl-S-alkyl, alkynyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkyl, hydroxy, hydroxyalkyl, —SH, N(O) 2 , and —NZ 1 Z 2 , wherein NZ 1 Z 2 means two groups Z 1 and Z 2 which are appended to the parent molecular moiety through a nitrogen atom, and wherein Z 1 and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, or formyl, or wherein Z 1 and Z 2 taken together with the nitrogen atom to which they are attached form a heterocyclic ring, optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, hydroxy, and haloalkyl;
A is a 4-, 5-, 6-, or 7-membered monocyclic heterocycle containing zero or one double bond, and one or two oxygen, and zero or one nitrogen as ring atoms wherein each A is independently unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of oxo, alkyl, —OH, and —O(alkyl); and
L 1 is a single bond.
2. The compounds of claim 1 , or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein A is (i), (ii), (iii), (iv), (v), or (vi)
3. The compound of claim 1 selected from the group consisting of
2,3-dichloro-N-[(2Z)-5-methyl-3-(tetrahydrofuran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
2,3-dichloro-N-[(2Z)-5-methyl-3-(tetrahydro-2H-pyran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
2-ethoxy-N-[(2Z)-5-methyl-3-(tetrahydro-2H-pyran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(tetrahydrofuran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(tetrahydro-2H-pyran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
2-ethoxy-N-[(2Z)-5-methyl-3-(tetrahydrofuran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(tetrahydrofuran-3-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
2-ethoxy-N-[(2Z)-5-methyl-3-(tetrahydrofuran-3-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
2-methoxy-N-[(2Z)-5-methyl-3-(tetrahydrofuran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
2-ethoxy-N-[(2Z)-5-methyl-3-(tetrahydro-2H-pyran-4-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
2,4-dimethoxy-N-[(2Z)-5-methyl-3-(tetrahydrofuran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(tetrahydro-2H-pyran-4-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-3-(tetrahydro-2H-pyran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-[(2S)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(oxetan-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-N-[(2Z)-3-(1,3-dioxolan-2-ylmethyl)-5-methyl-1,3-thiazol-2(3H)-ylidene]2-methoxybenzamide;
5-chloro-N-[(2Z)-3-[2-(1,3-dioxolan-2-yl)ethyl]-5-methyl-1,3-thiazol-2(3H)-ylidene]2-methoxybenzamide;
N-[(2Z)-3-(1,3-dioxolan-2-ylmethyl)-5-methyl-1,3-thiazol-2(3H)-ylidene]-2-ethoxybenzamide;
5-bromo-2-ethoxy-N-[(2Z)-5-methyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-ethoxy-N-[(2Z)-5-methyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]benzamide;
4-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]benzamide;
5-bromo-2-methoxy-N-[(2Z)-5-methyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(2-tetrahydro-2H-pyran-4-ylethyl)-1,3-thiazol-2-ylidene]benzamide;
5-chloro-N-[(2Z)-5-ethyl-3-(tetrahydrofuran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide;
5-chloro-2-methoxy-N-[(2Z)-5-propyl-3-(tetrahydrofuran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
4,5-dichloro-2-methoxy-N-[(2Z)-5-methyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-(tetrahydro-2H-pyran-3-ylmethyl)-1,3-thiazol-2(3H)-ylidene]benzamide;
5-chloro-2-methoxy-N-[(2Z)-5-methyl-3-[(3-methyl-4,5-dihydroisoxazol-5-yl)methyl]-1,3-thiazol-2(3H)-ylidene]benzamide;
5-bromo-N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide;
5-chloro-N-[(2Z)-3-(1,4-dioxan-2-ylmethyl)-5-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-(1,3-dioxolan-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-[(3-methyl-4,5-dihydroisoxazol-5-yl)methyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-(tetrahydro 2H-pyran-4-ylmethyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-[(3-methyloxetan-3-yl)methyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-(oxetan-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-(tetrahydro-2H-pyran-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-(1,4-dioxan-2-ylmethyl)-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-{[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-(tetrahydrofuran-3-ylmethyl)-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-(tetrahydro-2H-pyran-3-ylmethyl)-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-{[(2S)-5-oxotetrahydrofuran-2-yl]methyl}-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-[(5-methyltetrahydrofuran-2-yl)methyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-[(5,5-dimethyltetrahydrofuran-2-yl)methyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;
N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-(2-methoxyethoxy)benzamide;
N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-isopropoxybenzamide; and
N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]-5-chloro-2-ethoxybenzamide;
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising therapeutically effective amount of a compound of claim 1 of formula (I) or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
5. A method of treating neuropathic pain, nociceptive pain, and inflammatory pain in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of claim 1 of formula (I) or a pharmaceutically acceptable salt thereof.